SAFLY yields 50.31% · JNJ yields 2.13%● Live data
📍 SAFLY pulled ahead of the other in Year 1
Combined, SAFLY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SAFLY + JNJ for your $10,000?
Safilo Group S.p.A. engages in the design, production, wholesale, and retail distribution of products for the eyewear market in North America, Europe, the Asia Pacific, and internationally. Its brand portfolio comprises a set of own branded products, such as optical frames, sunglasses, sports goggles, and helmets, as well as licensed brands,including prescription frames and sunglasses. The company offers its products under own brands comprising Carrera, Polaroid, Safilo, Smith, Blenders Eyewear, and Privé Revaux, as well as Adensco, Chesterfield, Elasta, and Emozioni; and licensed brands, such as Banana Republic, BOSS, Carolina Herrera, Chiara Ferragni, David Beckham, Dsquared2, Fossil, havaianas, HUGO, Isabel Marant, Jimmy Choo, Juicy Couture, Kate Spade, LEVI'S, Liz Claiborne, Marc Jacobs, Missoni, M Missoni, Moschino and Love Moschino, Pierre Cardin, PORTS, rag&bone, Rebecca Minkof, Tommy Hilfiger, Tommy Jeans, Under Armour, and Liz Claiborne brand. It serves opticians, optometrists, ophthalmologists, distribution chains, department stores, specialized retailers, and licensors' own stores, as well as duty free and sports shops. The company sells its products through a network of independent distributor partners. The company was formerly known as Safilo Holding S.p.A. and changed its name to Safilo Group S.p.A. in September 2005. Safilo Group S.p.A. was founded in 1878 and is headquartered in Padua, Italy.
Full SAFLY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.